Products for Research Use Only
RegisterLogin

Bortezomib (Standard)

CAT: 0804-HY-10227R-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10227R-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Bortezomib (Standard) is the analytical standard of Bortezomib. This product is intended for research and analytical applications. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM) [1][2]. Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) [7].
CAS Number
179324-69-7
Product Name Alternative
PS-341 (Standard) ; LDP-341 (Standard) ; NSC 681239 (Standard)
UNSPSC
12352005
Target
Apoptosis; Autophagy; NF-κB; Proteasome; Reference Standards; TREM receptor
Type
Reference Standards
Related Pathways
Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Others
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bortezomib-standard.html
Purity
99.73
Smiles
OB(O)[C@H](CC(C)C)NC([C@@H](NC(C1=NC=CN=C1)=O)CC2=CC=CC=C2)=O
Molecular Formula
C19H25BN4O4
Molecular Weight
384.24
References & Citations
[1]Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59 (11) :2615-22.|[2]Shahshahan MA, et al. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastaticmelanoma: basic and clinical aspects. Am J Cancer Res. 2011;1 (7) :913-24.|[3]Pérez-Galán P, et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006 Jan 1;107 (1) :257-64.|[4]Yerlikaya A, et al. Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line. Mol Med Rep. 2010 Mar-Apr;3 (2) :333-9.|[5]Mujtaba T, et al. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med. 2011 Dec;12 (67) :471-80.|[6]Fernández Y, et al. Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death. J Biol Chem. 2006 Jan 13;281 (2) :1107-18.
Shipping Conditions
Blue Ice
Storage Conditions
4°C, sealed storage, away from light and moisture
Scientific Category
Reference Standards

Chemical Information

Bortezomib

Bortezomib is L-Phenylalaninamide substituted at the amide nitrogen by a 1-(dihydroxyboranyl)-3-methylbutyl group and at Nalpha by a pyrazin-2-ylcarbonyl group. It is a dipeptidyl boronic acid that reversibly inhibits the 26S proteasome. It has a role as an antineoplastic agent, an antiprotozoal drug, a protease inhibitor and a proteasome inhibitor. It is an amino acid amide, a member of pyrazines and a L-phenylalanine derivative. It is functionally related to a boronic acid.

CAS Number179324-69-7
PubChem CID387447
IUPAC Name[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
Molecular FormulaC19H25BN4O4
Molecular Weight384.2
Topological Polar Surface Area124
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count6
Rotatable Bond Count9
Heavy Atom Count28
Formal Charge0
Complexity500
SMILES
B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
InChI
InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
InChIKey
GXJABQQUPOEUTA-RDJZCZTQSA-N
Chemical Structure
2D Structure
2D structure of Bortezomib
CAS: 179324-69-7
CID: 387447
Formula: C19H25BN4O4
MW: 384.2
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight384.2
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count6
Rotatable Bond Count9
Exact Mass384.1968855
Monoisotopic Mass384.1968855
Topological Polar Surface Area124 Ų
Heavy Atom Count28
Formal Charge0
Complexity500
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Related Products

CatalogName
HY-10227-01Bortezomib
HY-W048404-01Bortezomib impurity A
HY-10227GBortezomib (GMP)
HY-169144Bortezomib analog
HY-10227S-01Bortezomib-d8
HY-125939-01Bortezomib-pinanediol
HY-135396-01(1S,2S) -Bortezomib
HY-Z4561S-01Bortezomib trimer-d15
HY-W048407Bortezomib impurity 12
HY-169158Bortezomib analog 1

Alternative Products

CatalogName
TRC-B675700-10MGBortezomib

Popular Products